Hospital
Munson Healthcare Cadillac
Munson Healthcare Cadillac was paid $21.55M by Medicaid between Jan 2018 and Dec 2024, across 292 billing codes. Its largest line is 99283, emergency room visit (moderate) — 14% of everything it billed.
33Billing provider infoMUNSON HEALTHCARE CADILLAC
CADILLAC, MI 49601
CADILLAC, MI 49601
33aNPI1841696754assigned 11/05/2014
33bProvider typeGeneral Acute Care Hospital
28Total paid$21.55M
24GClaims839,920
24DCodes billed292
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#44 of 86
Median peer was paid$21.55M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 114,002 | $2.60M | |
| 2019 | 121,468 | $2.72M | |
| 2020 | 111,954 | $2.70M | |
| 2021 | 127,260 | $3.48M | |
| 2022 | 131,133 | $3.50M | |
| 2023 | 133,076 | $3.43M | |
| 2024incomplete | 101,027 | $3.14M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 24,438 | 23,133 | $2.98M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 12% | 41,381 | 37,991 | $2.53M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 8,431 | 7,961 | $2.42M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 12,161 | 11,597 | $2.28M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.0% | 13,482 | 11,963 | $1.28M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.8% | 11,393 | 11,085 | $812K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.1% | 4,540 | 4,401 | $667K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.7% | 18,808 | 5,792 | $375K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.7% | 11,769 | 9,713 | $363K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 10,636 | 9,049 | $333K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 4,045 | 3,197 | $327K |
| 71045 | Radiologic examination, chest; single view | 1.5% | 8,296 | 7,838 | $318K |
280 more codes
| 59025 | Fetal non-stress test | 1.3% | 3,349 | $285K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 3,312 | $280K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 5,968 | $278K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.2% | 2,583 | $249K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1.1% | 98 | $246K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 1,102 | $232K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 5,792 | $216K |
| G0378 | Hospital observation service, per hour | <1% | 838 | $207K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 7,965 | $196K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,702 | $186K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,413 | $180K |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 45 | $161K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,741 | $156K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 811 | $151K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,157 | $144K |
| 76830 | Ultrasound, transvaginal | <1% | 2,427 | $141K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,610 | $141K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,191 | $135K |
| 80061 | Lipid panel | <1% | 7,688 | $133K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 9,285 | $133K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,277 | $126K |
| 76801 | <1% | 2,054 | $121K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 6,151 | $112K |
| 97161 | <1% | 2,111 | $104K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 331 | $93K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,191 | $86K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,186 | $86K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,572 | $79K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,321 | $78K |
| 80053 | Comprehensive metabolic panel | <1% | 33,444 | $74K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 917 | $74K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 12,491 | $73K |
| 86900 | <1% | 2,993 | $67K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 44,263 | $66K |
| 36415 | Collection of venous blood by venipuncture | <1% | 58,924 | $60K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,870 | $55K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,444 | $52K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,014 | $50K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,500 | $46K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,032 | $44K |
| 92526 | <1% | 996 | $43K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 503 | $40K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,210 | $39K |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 2,542 | $38K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 121 | $38K |
| 97165 | <1% | 822 | $38K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,561 | $34K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,722 | $34K |
| 76642 | <1% | 873 | $33K | |
| 73564 | <1% | 1,782 | $32K | |
| 93971 | <1% | 585 | $32K | |
| 74018 | <1% | 1,713 | $31K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,010 | $29K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,849 | $29K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,063 | $28K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 54 | $28K |
| 94726 | <1% | 477 | $27K | |
| 94060 | <1% | 191 | $26K | |
| 86780 | <1% | 3,307 | $24K | |
| 82728 | <1% | 3,437 | $23K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 245 | $22K |
| 93017 | <1% | 609 | $22K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,367 | $22K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,349 | $21K |
| 64721 | <1% | 26 | $19K | |
| 71271 | <1% | 372 | $19K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 155 | $19K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 715 | $19K |
| 76536 | <1% | 384 | $18K | |
| 73630 | <1% | 2,327 | $18K | |
| 73030 | <1% | 1,560 | $17K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,936 | $16K |
| 85027 | <1% | 5,954 | $16K | |
| 81025 | <1% | 13,707 | $15K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,203 | $15K |
| 73610 | <1% | 2,089 | $15K | |
| 72110 | <1% | 625 | $14K | |
| 84702 | <1% | 2,757 | $13K | |
| 73130 | <1% | 1,925 | $13K | |
| 82607 | <1% | 1,817 | $13K | |
| 87641 | <1% | 690 | $12K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 24 | $12K |
| 87340 | <1% | 2,406 | $12K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,086 | $12K |
| 73110 | <1% | 1,402 | $12K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 28 | $11K |
| 87640 | <1% | 606 | $11K | |
| 86762 | <1% | 1,491 | $11K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 374 | $11K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,171 | $11K |
| 84439 | <1% | 2,468 | $10K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,113 | $10K |
| 87653 | <1% | 559 | $9K | |
| 77065 | Tomosynthesis, mammo | <1% | 220 | $9K |
| 87077 | <1% | 3,926 | $8K | |
| 81001 | <1% | 23,277 | $8K | |
| 97162 | <1% | 206 | $8K | |
| 87186 | <1% | 3,523 | $8K | |
| 86803 | <1% | 1,121 | $8K | |
| 86850 | <1% | 2,982 | $8K | |
| 83970 | <1% | 369 | $8K | |
| 87150 | <1% | 592 | $8K | |
| 97116 | <1% | 784 | $8K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 241 | $7K |
| 87480 | <1% | 852 | $7K | |
| 82570 | <1% | 2,728 | $7K | |
| 87660 | <1% | 847 | $7K | |
| 87510 | <1% | 842 | $6K | |
| 83735 | <1% | 7,618 | $6K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 605 | $6K |
| 86787 | <1% | 921 | $6K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 7,244 | $6K |
| 83550 | <1% | 1,415 | $6K | |
| 83540 | <1% | 1,808 | $6K | |
| 85610 | <1% | 7,870 | $6K | |
| 72100 | <1% | 209 | $6K | |
| 73502 | <1% | 531 | $5K | |
| C9399 | Unclassified drugs or biologicals | <1% | 134 | $5K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,169 | $5K |
| 93225 | <1% | 81 | $5K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 12 | $5K |
| 76775 | <1% | 167 | $5K | |
| 82043 | <1% | 1,549 | $5K | |
| 73221 | <1% | 37 | $4K | |
| 87081 | <1% | 3,825 | $4K | |
| 87210 | <1% | 2,092 | $4K | |
| 82950 | <1% | 1,646 | $4K | |
| 83880 | <1% | 1,612 | $4K | |
| 95806 | <1% | 51 | $4K | |
| 71250 | <1% | 81 | $4K | |
| 77066 | Tomosynthesis, mammo | <1% | 74 | $4K |
| 87070 | <1% | 1,904 | $4K | |
| 82947 | <1% | 1,758 | $4K | |
| 80076 | <1% | 3,965 | $4K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 349 | $3K |
| 36430 | <1% | 22 | $3K | |
| 86140 | <1% | 2,958 | $3K | |
| 81003 | <1% | 5,481 | $3K | |
| 87088 | <1% | 1,415 | $3K | |
| 85652 | <1% | 3,076 | $3K | |
| 74019 | <1% | 110 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,322 | $3K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 64 | $3K |
| 73140 | <1% | 340 | $3K | |
| 87507 | <1% | 15 | $3K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 302 | $2K |
| 74022 | <1% | 987 | $2K | |
| 83690 | <1% | 8,006 | $2K | |
| 85730 | <1% | 4,909 | $2K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 135 | $2K |
| 87634 | <1% | 148 | $2K | |
| 87205 | <1% | 1,926 | $2K | |
| 73080 | <1% | 221 | $2K | |
| 96415 | <1% | 62 | $2K | |
| 94010 | <1% | 133 | $1K | |
| 72070 | <1% | 78 | $1K | |
| 70491 | <1% | 13 | $1K | |
| 84100 | <1% | 1,530 | $1K | |
| 71101 | <1% | 121 | $1K | |
| 84156 | <1% | 851 | $1K | |
| 80069 | <1% | 265 | $1K | |
| 82150 | <1% | 2,031 | $1K | |
| 81002 | <1% | 657 | $1K | |
| 73090 | <1% | 169 | $977.16 | |
| 86039 | <1% | 177 | $975.77 | |
| 88304 | <1% | 677 | $964.90 | |
| 84146 | <1% | 97 | $926.72 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 51 | $916.07 |
| 82746 | <1% | 125 | $878.24 | |
| 82077 | <1% | 2,966 | $859.68 | |
| 86901 | <1% | 2,986 | $801.43 | |
| 86038 | <1% | 144 | $801.38 | |
| 83001 | <1% | 76 | $780.32 | |
| 82565 | <1% | 348 | $752.21 | |
| 76770 | <1% | 14 | $741.52 | |
| 96417 | <1% | 35 | $638.88 | |
| 36591 | <1% | 31 | $625.83 | |
| 85379 | <1% | 2,318 | $614.70 | |
| 72131 | <1% | 12 | $593.09 | |
| 72114 | <1% | 13 | $562.26 | |
| 73590 | <1% | 129 | $492.75 | |
| 87807 | <1% | 1,059 | $459.65 | |
| 85046 | <1% | 160 | $455.51 | |
| 76870 | <1% | 13 | $453.88 | |
| 12001 | <1% | 448 | $443.19 | |
| 84403 | <1% | 38 | $365.49 | |
| 87040 | <1% | 2,399 | $320.07 | |
| 84703 | <1% | 448 | $316.95 | |
| 84550 | <1% | 199 | $297.33 | |
| 84484 | <1% | 6,682 | $268.88 | |
| 82962 | <1% | 5,102 | $259.56 | |
| 82248 | <1% | 147 | $233.78 | |
| 87522 | Neg quan hep c or qual rna | <1% | 14 | $225.82 |
| 86431 | <1% | 80 | $210.91 | |
| 88342 | <1% | 16 | $210.33 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 13 | $206.87 |
| 82784 | <1% | 42 | $203.07 | |
| 83516 | <1% | 26 | $191.04 | |
| 83615 | <1% | 103 | $169.33 | |
| 80143 | <1% | 1,674 | $147.82 | |
| 80179 | <1% | 1,654 | $135.54 | |
| 84153 | <1% | 12 | $111.82 | |
| 90715 | <1% | 917 | $111.65 | |
| 83605 | <1% | 5,551 | $96.24 | |
| 82550 | <1% | 88 | $88.68 | |
| 93226 | <1% | 68 | $64.79 | |
| 87328 | <1% | 12 | $50.58 | |
| 82272 | <1% | 142 | $49.21 | |
| 87899 | <1% | 13 | $45.14 | |
| 87329 | <1% | 12 | $43.86 | |
| 87427 | <1% | 13 | $36.73 | |
| 86308 | <1% | 73 | $31.94 | |
| 87046 | <1% | 13 | $28.23 | |
| 87045 | <1% | 13 | $28.09 | |
| 85018 | <1% | 29 | $20.88 | |
| 84145 | <1% | 59 | $17.93 | |
| 88300 | <1% | 177 | $13.93 | |
| 85014 | <1% | 13 | $12.48 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,853 | $11.80 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,220 | $0.48 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,595 | $0.24 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 764 | $0.24 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,735 | $0.24 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 171 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 3,165 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 1,569 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 1,105 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 3,826 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 313 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 5,791 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 175 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 352 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,713 | $0.00 |
| 94729 | 0% | 618 | $0.00 | |
| 84112 | 0% | 120 | $0.00 | |
| S0028 | Injection, famotidine, 20 mg | 0% | 28 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 85 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 158 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 130 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 202 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 275 | $0.00 |
| 76942 | 0% | 15 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 12 | $0.00 |
| 12011 | 0% | 12 | $0.00 | |
| 29125 | 0% | 13 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 2,650 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 2,258 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 5,054 | $0.00 |
| J3490 | Unclassified drugs | 0% | 452 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 4,974 | $0.00 |
| 96376 | 0% | 3,011 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 867 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 5,613 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 2,153 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 1,991 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 2,787 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 1,770 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 90 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 300 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 6,118 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 259 | $0.00 |
| 94760 | 0% | 270 | $0.00 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 40 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 90 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 29 | $0.00 |
| 12002 | 0% | 15 | $0.00 | |
| J0592 | Injection, buprenorphine hydrochloride, 0.1 mg | 0% | 184 | $0.00 |
| 82803 | 0% | 38 | $0.00 | |
| 72170 | 0% | 41 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 96 | $0.00 |
| 94644 | 0% | 45 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 15 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 103 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 38 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 31 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 111 | $0.00 |
| A9270 | Non-covered item or service | 0% | 167 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 12 | $0.00 |
| 96368 | 0% | 15 | $0.00 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMARINOFF, PETER (PRESIDENT/CEO SOUTH REIGON)
Parent organizationMUNSON HEALTHCARE
| Provider | Location | Paid |
|---|---|---|
| Paul Oliver Memorial Hospital | Frankfort, MI | $3.03M |
| Munson Healthcare Cadillac | Cadillac, MI | $50K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.